Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Therapeutic options targeting intrahepatic resistance are ve
2020-12-11

Therapeutic options targeting intrahepatic resistance are very limited. Theoretically, the NO-cGMP pathway may be influenced at several sites. Yet, most strategies did not reach clinical practice or yielded disappointing results, such as activators of soluble guanylate cyclase [14], NO releasing der
-
Enlarging the ligand binding pocket by reduction of the size
2020-12-11

Enlarging the ligand-binding pocket by reduction of the size of the residue F435 switched DES to an agonist indicating that F435 is involved in mediating the antagonistic effect of DES (Fig. 7E) [13]. The conformation of the smaller side chain of L435 was either not altered by DES or was too small t
-
br Experimental section br Acknowledgments This work was sup
2020-12-11

Experimental section Acknowledgments This work was supported by the National Natural Science Foundation of China (NSFC, Grant No. 81573285 and No. 81602965), the Natural Science Basic Research Plan in Shaanxi Province of China (Program No. 2018JM7071 and No. 2017JQ8002), and the Fundamental Re
-
br Conflict of interest br Supplementary methods and materia
2020-12-11

Conflict of interest Supplementary methods and materials Acknowledgments This work was supported by an Early Career Researcher grant awarded by the Institute of Health and Biomedical Innovation to IMW and Queensland University of Technology, and grants awarded to SS by the Prostate Cancer F
-
The enantiomeric ratio ER of chiral compounds accumulated in
2020-12-11

The enantiomeric ratio (ER) of chiral compounds accumulated in organisms has been found to be different among species (Borga and Bidleman, 2005, Harner et al., 1999, Warner et al., 2005, Wiberg et al., 2000), indicating enantioselective accumulation of chiral compounds are species-specific. The ER o
-
br Methods br Results br Discussion
2020-12-10

Methods Results Discussion Preclinical data indicate that nepicastat modulates sympathetic drive to the m1v1 m2v2 calculator with a mild pressor effect in various animal models of hypertension (Stanney et al., 1998). However in this clinical study, the doses of nepicastat employed did not
-
DNA methylation assay To test the
2020-12-10

DNA methylation assay. To test the biological activity of purified A1S_0222, a methylation assay was performed using the Int1 DNA. As an alternative DNA substrate, Seq3 (located in gene A1S_0965 of A. baumannii ATCC 17978) was amplified from Acinetobacter baumannii 29D2 using the oligonucleotides Se
-
In the gel shown in Figure at early time
2020-12-10

In the gel shown in Figure 8, at early time-points, 14% of the input dsDNA is converted to these intermediate species. These persist in the gel to later times, with approximately 50% of these being unwound. This unwinding occurs at a considerably slower rate and is due to that fraction of the popula
-
DGK is not the only DGK isoform that has
2020-12-10

DGKε is not the only DGK isoform that has been associated with p53. It has been shown that DGKζ binds to p53 and modulates its activity in both the cytoplasm and the nucleus [39]. In the cytosol DGKζ promotes the degradation of p53 through the ubiquitin-proteosome system [39], also a likely mechanis
-
muscarinic receptor antagonists In this study we examined a
2020-12-10

In this study, we examined a possible association between the 19-bp muscarinic receptor antagonists and the 9-bp repeat in the DHFR gene and the risk of spina bifida in 121 mothers of a spina bifida affected child, 292 control women, 109 spina bifida patients and 234 pediatric controls using a case-
-
In Senegal malaria remains a formidable
2020-12-10

In Senegal, malaria remains a formidable public health issue, causing significant morbidity and mortality in infants and pregnant women (WHO Malaria Report, 2012). In the absence of an effective vaccine, the National Malaria Control Program has followed WHO recommendations for IPTp-SP since 2003. Th
-
In order to derive a
2020-12-10

In order to derive a better understanding of the results from our SAR study, we utilized Glide to model the binding of the SAR compounds with the non-active site pocket of TS-DHFR shown in C. The majority of models position the phenolic moiety of these compounds within the non-active site pocket, wh
-
In the context of food allergy it is hypothesized
2020-12-10

In the context of food allergy it is hypothesized that intestinal barrier dysfunction might contribute to both antigen sensitization and the IgE/mast cell mediated effector phase of allergic disease, however no concluding data has been published to date [5]. An understanding of the mechanism of prim
-
As previously reported azole class antifungal
2020-12-10

As previously reported, azole class antifungal drugs inhibit fungal CYP450 14α-demethylase, as this interrupts the conversion of lanosterol to ergosterol, a component of the fungal cell membrane (Hof, 2006). Furthermore, correlation between fluconazole dose, the extent of hepatic hypertrophy, the le
-
LY2157299 synthesis Alvocidib flavopiridol is a piperidine c
2020-12-10

Alvocidib (flavopiridol) is a piperidine-chromenone derivative (Fig. 6D) that is not FDA approved, but is in clinical trials for breast, endometrial, and several other cancers and hematological malignancies (Table 4) [[100], [101], [102], [103], [104]]. This drug targets CDK9 (IC50 = 3.2 nM) and CDK
16446 records 760/1097 page Previous Next First page 上5页 756757758759760 下5页 Last page